InDex Pharmaceuticals

InDex is a pharmaceutical development company focused on immunological diseases, where there is a high unmet medical need for new treatment options. The company’s most important asset is the candidate drug cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe active ulcerative colitis (a debilitating chronic inflammation of the large intestine). InDex has also developed a patented discovery-phase substance platform, known as DNA-based ImmunoModulatory Sequences (DIMS), which holds potential for the treatment of various immunological diseases.